Skip to main content
ScholarsBetaWeill Cornell Medicine

Highlights

  1. 1
    ACS chemical biology · 2023
    SSSubhash Sinha
    PMID: 38079390DOISenior author2 citations
  2. 2
    ACS medicinal chemistry letters · 2020
    SSSubhash Sinha
    PMID: 33062181PMCID: PMC7549266DOISenior author13 citations
  3. 3
    Frontiers in chemistry · 2024
    SSSubhash Sinha
    PMID: 39439934PMCID: PMC11493595DOISenior author

Publications

91 publications

Funding

20 grantsView NIH portfolio on RePORTER ↗

Active

8 grants
  • Co-I
    Developing Inhibitors of Mitochondrial Complex III-Derived ROS for the Treatment of Alzheimer's Disease
    National Institute on Aging · 2026–2030
    RF1AG095161-01A1
  • PI
    Optimization of covalent inhibitors of human CD33
    Cure Alzheimer’s Fund · 2027–2027
    CAF 264707-01
  • MPI
    cGAS inhibitors for Alzheimer's disease treatment
    National Institute on Aging · 2021–2027
    R01AG074541-05
  • Co-I
    Sex-biased TLR7 signaling in demyelination and its inhibition by small molecules
    Cure Alzheimer’s Fund · 2025–2026
    CAF 245217-01
  • Co-I
    Methods to optimize the human cGAS inhibitor leads
    Rainwater Charitable Foundation · 2025–2026
    RCF 250950-01
  • Co-I
    Acetylated Tau Immunotherapy for Alzheimer's Disease
    National Institute on Aging · 2024–2026 · via Aeton Therapeutics Inc.
    R41AG085770-01
  • Co-I
    Evaluation of a novel human cGAS inhibitor using human iPSC derived models
    Harrington Discovery Institute, The · 2024–2026
    HDIT 235842-01
  • PI
    Identification and development of CD33 inhibitors and pre-RNA splicing modulators
    Cure Alzheimer’s Fund · 2023–2026
    CAF 233173-02
Completed grants (12)
  • Co-I
    Methods to optimize the benzofuran and benzothiophene human cGAS inhibitor leads
    Rainwater Charitable Foundation · 2024–2025
    RCF 241018-01
  • KP
    Optimize virtual hits of human CGAS inhibitor to treat neurodegeneration
    National Institute on Aging · 2023–2025 · via Aeton Therapeutics Inc.
    R43AG080954-01
  • Co-I
    Rainwater Drug Discovery Grant
    Rainwater Charitable Foundation · 2023–2024
    RCF 230888-01
  • Co-I
    Human cGAS small molecule inhibitors
    Cure Alzheimer’s Fund · 2021–2024
    CAF 213682-01
  • Co-I
    Development of cGAS Inhibitors to Treat Neurodegenerative Diseases
    Daedalus Fund for Innovation (Weill Cornell) · 2021–2024BioPharma Alliance
    BP 214753-01
  • PI
    vHTS for CD33 inhibitors
    Cure Alzheimer’s Fund · 2021–2023
    CAF 212347-02
  • Co-I
    Development of best-of-class Inhibitors of cGAS to treat tauopathy
    Rainwater Charitable Foundation · 2021–2022
    RCF 221502-01
  • Co-I
    Lead Optimization of Novel Site-Selective Blockers of Mitochondrial Complex III ROS as FTD Therapeutics
    Alzheimer's Drug Discovery Foundation · 2021–2022
    GA-202007-2020603
  • PI
    Developing compounds for Alzheimer disease target discovery and therapy
    JPB Foundation, The · 2020–2021
    JPG 205199-01
  • PI
    Cure Alzheimer's Fund Subhash Sinha grant transfer from Rockefeller
    Cure Alzheimer’s Fund · 2020–2020
    CAF 211021-01
  • PI
    Selective Antibody Conjugates
    NCI · 2007–2011 · via NIH RePORTER
    R01CA120289-04
  • PI
    Asymmetric Aminocatalysis
    NIGMS · 2002–2005 · via NIH RePORTER
    R01GM063914-02

News mentions

1 mentionView all WCM news ↗

Mentoring

4 menteesAll publications with mentees →

External relationships

Ownership

Aeton Therapeutics Inc. · LSG Therapeutics, LLC

Proprietary Interest

Aeton Therapeutics Inc.

Other

Aeton Therapeutics Inc. · CGA Therapeuticals Incorporated · LSG Therapeutics, LLC